BioSpace News Archive

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), today announced that the Company has suspended patient enrollment in its Phase 2b study of XOWNA®, known as the FREEDOM Trial, for the treatment of coronary microvascular dysfunction (“CMD”).

The rising prevalence of chronic diseases and increasing penetration of home healthcare services & remote use of devices are the key factors driving the product demand.

Statera Biopharma announced the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC on May 18, 2022 indicating that, because the Company was delinquent in filing its quarterly report on Form 10-Q on May 15, 2022 for the first quarter ended March 31, 2022, the Company had not complied with Nasdaq Listing Rule 5250 for continued listing.

Sensus Healthcare, Inc. announces that management will be participating in the H.C. Wainwright Global Investment Conference taking place virtually and in-person at the Fontainebleau Miami Beach May 23-26, 2022.

The volume of surgical operations has increased with the rising incidence of chronic respiratory illnesses, such as Cardiovascular Diseases (CVDs), diabetes, respiratory diseases, cancer, or other respiratory injuries.

SHINE Technologies, LLC, a next-generation nuclear technology company, announced Chris Vessell has joined as General Manager of the Therapeutics Division.

Acasti Pharma Inc. (Nasdaq: ACST and TSX-V: ACST) (“Acasti"; the “Company”), has retained one of the industry’s leading investor relations firms, Lytham Partners, LLC, to lead a strategic investor relations and shareholder communication program.

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (“4Front” or the “Company”), a vertically integrated, multi-state cannabis operator and retailer, today announced its financial results for the first quarter ended March 31, 2022 (“Q1 2022").